Boston Scientific (NYSE:BSX) Given New $90.00 Price Target at Stifel Nicolaus

Boston Scientific (NYSE:BSX) had its price objective trimmed by Stifel Nicolaus from $110.00 to $90.00 in a report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the medical equipment provider’s stock.

BSX has been the subject of a number of other research reports. TD Cowen dropped their price objective on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Morgan Stanley decreased their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Wells Fargo & Company lowered their price target on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Oppenheimer dropped their price target on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $97.00 price objective on shares of Boston Scientific in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $106.27.

Boston Scientific Stock Down 0.5%

Shares of BSX stock opened at $69.54 on Friday. The company has a market capitalization of $103.34 billion, a price-to-earnings ratio of 35.84, a PEG ratio of 0.98 and a beta of 0.69. Boston Scientific has a one year low of $67.56 and a one year high of $109.50. The company’s fifty day moving average price is $79.74 and its 200-day moving average price is $92.15. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the company earned $0.70 EPS. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts expect that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the last quarter. State Street Corp lifted its stake in Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Synergy Asset Management LLC lifted its stake in Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after purchasing an additional 479,593 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its position in shares of Boston Scientific by 39.5% during the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after buying an additional 14,700 shares during the period. Finally, Kepler Cheuvreux Suisse SA bought a new position in shares of Boston Scientific during the third quarter valued at approximately $26,955,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham/analyst support — Needham & Company maintained a Buy rating and $97 price target, arguing the financial fallout from the Accolade pacemaker recalls is limited and supports a continued Buy stance. Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
• Neutral Sentiment: Stifel trims target but keeps Buy — Stifel cut its price target from $110 to $90 while retaining a Buy rating, reducing upside expectations even as the firm remains constructive. Benzinga: Stifel Nicolaus Price Target
• Neutral Sentiment: Other firms lower expectations — Truist and UBS have lowered price targets/expectations (Truist to $92), signaling more cautious analyst views on near-term growth despite mixed analyst conviction. Truist Lowers Boston Scientific Price Target to $92
• Negative Sentiment: Multiple securities class-action alerts — Several law firms have filed or are soliciting lead plaintiffs for securities fraud suits tied to disclosures covering July 2025–Feb 2026; reminders and deadlines (May 4, 2026) are fueling legal uncertainty and potential future liability. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: NYT report alleges long-standing battery issues — The New York Times reports Boston Scientific was aware of pacemaker battery problems for years, a story that raises reputational and regulatory risk beyond the company’s stated scope. Boston Scientific Knew of Pacemaker Battery Problems for Years
• Negative Sentiment: Recall expanded — Market chatter notes Boston Scientific amended its Accolade pacemaker recall, increasing the affected population to ~1.6 million devices, which raises potential remediation costs and investor concern. Market Chatter: Boston Scientific Amends Recall of Accolade Pacemakers, Affected Population Now 1.6 Million
• Negative Sentiment: High-profile criticism — Jim Cramer publicly criticized BSX’s recent performance and competitive pressures, a sentiment that can influence retail flows and short-term sentiment. Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore”

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.